TLC Reports First Quarter 2020 Financial Results and Provides Business Update
May 13, 2020 04:12 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 13, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Earns Highest Ranking in Corporate Governance Evaluation Six Years in a Row
May 04, 2020 05:47 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 04, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC to Present at 38th Annual JP Morgan Healthcare Conference
January 02, 2020 04:00 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Jan. 02, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Announces First Patient Enrollment in EXCELLENCE Trial Evaluating Single and Repeat Administrations of TLC599
November 27, 2019 04:30 ET
|
TLC
Phase III clinical trial of TLC599 to recruit 500 patients with moderate to severe symptomatic knee osteoarthritis Patients can receive two injections of placebo or drugPatient enrollment expected to...
TLC to Present at Upcoming Investor Conferences in September 2019
August 28, 2019 05:00 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 28, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152) today announced that the management team is scheduled to present at the two upcoming...
TLC and 3SBio Form Exclusive Partnership to Commercialize Two NanoX™ Products in Mainland China
March 03, 2019 21:57 ET
|
Taiwan Liposome Company, Ltd.
SOUTH SAN FRANCISCO, Calif., TAIWAN, SHEN YANG, China and HONG KONG, March 04, 2019 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (“TLC”)(Nasdaq: TLC, TWO: 4152), a clinical-stage specialty...
Taiwan Liposome Company Reports Positive Top-Line Data from Phase II Clinical Trial of TLC599 in Knee Osteoarthritis Pain
August 20, 2018 08:19 ET
|
Taiwan Liposome Company, Ltd.
Primary endpoint and key secondary endpoints metTLC599 demonstrated statistically significant improvement over placebo through Weeks 12, 16, 20, and 24 TLC599 was well-tolerated with no...
TLC Reports Last Patient Last Visit (LPLV) in TLC599 Phase II Trial and FDA Clearance to Commence New Clinical Trials
July 09, 2018 15:01 ET
|
Taiwan Liposome Company, Ltd.
LPLV marks the final steps toward completion of TLC599 trial for osteoarthritis (OA) painPhase II topline results on-track for 2018 releaseSet to initiate enrollment of US Phase II pharmacokinetic...